Literature DB >> 18037523

FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review.

Tao Liu1, Wen Xu, Wei-Li Yan, Ming Ye, Yong-Rui Bai, Gang Huang.   

Abstract

PURPOSE: To perform a systematic review to compare FDG-PET, CT, and MRI imaging for diagnosis of local residual or recurrent nasopharyngeal carcinoma.
MATERIALS AND METHODS: MEDLINE, EMBASE, the CBMdisc databases and some other databases were searched for relevant original articles published from January 1990 to June 2007. Inclusion criteria were as follows: Articles were reported in English or Chinese; FDG-PET, CT, or MRI was used to detect local residual or recurrent nasopharyngeal carcinoma; histopathologic analysis and/or close clinical and imaging follow-up for at least 6 months were the reference standard. Two reviewers independently extracted data. A software called "Meta-DiSc" was used to obtain pooled estimates of sensitivity, specificity, diagnostic odds ratio (DOR), summary receiver operating characteristic (SROC) curves, and the Q* index.
RESULTS: Twenty-one articles fulfilled all inclusion criteria. The pooled sensitivity estimates for PET (95%) were significantly higher than CT (76%) (P<0.001) and MRI (78%) (P<0.001). The pooled specificity estimates for PET (90%) were significantly higher than CT (59%) (P<0.001) and MRI (76%) (P<0.001). The pooled DOR estimates for PET (96.51) were significantly higher than CT (7.01) (P<0.001) and MRI (8.68) (P<0.001). SROC curve for FDG-PET showed better diagnostic accuracy than CT and MRI. The Q* index for PET (0.92) was significantly higher than CT (0.72) (P<0.001) and MRI (0.76) (P<0.01). For PET, the sensitivity and diagnostic OR for using qualitative analysis were significantly higher than using both qualitative and quantitative analyses (P<0.01). For CT, the sensitivity, specificity, diagnostic OR, and the Q* index for dual-section helical and multi-section helical were all significantly higher than nonhelical and single-section helical (P<0.01). And the sensitivity for 'section thickness <5 mm' was significantly lower than ' =5 mm' (P<0.01), while the specificity was significantly higher (P<0.01). For MRI, there were no significant differences found between magnetic field strength <1.5 and > or =1.5 T (P>0.05).
CONCLUSION: FDG-PET was the best modality for diagnosis of local residual or recurrent nasopharyngeal carcinoma. The type of analysis for PET imaging and the section thickness for CT would affect the diagnostic results. Dual-section helical and multi-section helical CT were better than nonhelical and single-section helical CT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18037523     DOI: 10.1016/j.radonc.2007.11.002

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  29 in total

1.  64-row MDCT perfusion of head and neck squamous cell carcinoma: technical feasibility and quantitative analysis of perfusion parameters.

Authors:  Lorenzo Faggioni; Emanuele Neri; Francesca Cerri; Eugenia Picano; Veronica Seccia; Luca Muscatello; Stefano Sellari Franceschini; Carlo Bartolozzi
Journal:  Eur Radiol       Date:  2010-07-23       Impact factor: 5.315

Review 2.  Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge.

Authors:  Tao Xu; J Tang; M Gu; L Liu; W Wei; H Yang
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

3.  FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.

Authors:  Yuko Suenaga; Kazuhiro Kitajima; Takeaki Ishihara; Ryohei Sasaki; Naoki Otsuki; Ken-Ichi Nibu; Tsutomu Minamikawa; Naomi Kiyota; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2015-07-19       Impact factor: 5.315

4.  Value of 18F-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence.

Authors:  Seung Hwan Moon; Young Seok Cho; Young-Ik Son; Yong Chan Ahn; Myung-Ju Ahn; Joon Young Choi; Byung-Tae Kim; Kyung-Han Lee
Journal:  Br J Radiol       Date:  2016-09-21       Impact factor: 3.039

5.  Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT.

Authors:  Shu-Hang Ng; Sheng-Chieh Chan; Tzu-Chen Yen; Chun-Ta Liao; Joseph Tung-Chieh Chang; Sheung-Fat Ko; Hung-Ming Wang; Chin-Yu Lin; Kai-Ping Chang; Yu-Chun Lin
Journal:  Eur Radiol       Date:  2010-09       Impact factor: 5.315

Review 6.  Role of (18)F-FDG PET-CT in head and neck squamous cell carcinoma.

Authors:  P Castaldi; L Leccisotti; F Bussu; F Miccichè; V Rufini
Journal:  Acta Otorhinolaryngol Ital       Date:  2013-02       Impact factor: 2.124

7.  Nasopharyngeal carcinoma: 30-year experience of a single institution in a non-endemic area.

Authors:  J García-Lorenzo; N Farre; A Codina; O Gallego; M De Vega; X León
Journal:  Clin Transl Oncol       Date:  2017-01-24       Impact factor: 3.405

8.  18F-fluorodeoxyglucose positron emission tomography for predicting tumor response to radiochemotherapy in nasopharyngeal carcinoma.

Authors:  Meng Su; Liang Zhao; Hangping Wei; Ruifang Lin; Xuebang Zhang; Changlin Zou
Journal:  Strahlenther Onkol       Date:  2015-05-17       Impact factor: 3.621

9.  The role of changes in maximum standardized uptake value of FDG PET-CT for post-treatment surveillance in patients with head and neck squamous cell carcinoma treated with chemoradiotherapy: preliminary findings.

Authors:  Munetaka Matoba; Hiroyuki Tuji; Yuzo Shimode; Tamaki Kondo; Kiyotaka Oota; Hisao Tonami
Journal:  Br J Radiol       Date:  2017-01-05       Impact factor: 3.039

10.  Impact of nonhybrid 99mTc-MDP-SPECT/CT image fusion in diagnostic and treatment of oromaxillofacial malignancies.

Authors:  Denys John Loeffelbein; Eckhart Mielke; Andreas Konrad Buck; Marco Rainer Kesting; Frank Hölzle; Thomas Mücke; Steffen Müller; Klaus-Dietrich Wolff
Journal:  Mol Imaging Biol       Date:  2009-05-09       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.